CAS: 3034-55-7; 5-Bromothiazole

该化合物是一种杂环有机化合物,在硫氨环的5个位置上有一个溴替代物,这种多用途中间体广泛用于制药和农用化学合成,因为它在交叉反应中具有反应性,如Suzuki-Miyaura和Buchwald-Hartwig,其电子衰竭的硫醇核心提高了其在制造复杂分子特别是生物活性化合物开发过程中的效用.溴混合物为进一步功能化提供了战略处理器,能够进行精确的修改.由于高度纯度和稳定性,5-溴-1,3-thiazole是研究医药化学和物质科学应用的可靠建筑块.

英文名称5-Bromothiazole
中文名称5-溴噻唑
IUPAC名称5-bromothiazole
其它别名Thiazole, 5-bromo-; 5-Bromothiazole,
CAS编号3034-55-7
MFCD编号:MFCD07787394
EINECS号:628-697-2
分子式:C3H2BrNS
分子量:164.02
产品CID: 1288122
产品分类有机原料 → 杂环化合物

相似结构搜索
InChIKey: DWUPYMSVAPQXMS-UHFFFAOYSA-N
InChI=1S/C3H2BrNS/c4-3-1-5-2-6-3/h1-2H…
计算化学: 氢键受体数2.0氢键供体数0.0可旋转键数0.0

MSDS等安全信息

GHS象形图
GHS符号GHS07 & GHS05;
注释: Exclamation mark & Corrosion
危险类别急性毒性类别4(经口)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼损伤类别1
皮肤致敏类别1
易燃液体类别4
严重眼刺激类别2
警示词Danger(危险)
危险描述H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H318 |造成严重眼损伤.
H317 |可能引起皮肤过敏反应.
H227 |可燃液体
H319 |造成严重眼刺激.
防范说明P261-P264-P280-P301+P312-P302+P352-P305+P351+P338
UN编号NA 1993 / PGIII
危险品标志Xn,Xi
安全声明26-36/37/39
危险类别码22-37/38-41-43
WGK Germany3

欧盟法规

ECHA物质C&L通报

上下游产品

合成工艺路线路线简述

合成目标产物 5-Bromothiazole 主要起始原料 2-Amino-5-Bromothiazole
(文献来源)合成步骤主要原料 2-Amino-5-Bromothiazole

2-氨基-5-溴噻唑置于磷酸,硝酸,Sodium Nitrite体系中,用水作为反应溶剂,化学反应 0.5H,以54%的收率获得产物5-溴噻唑
参考文献:顺序溴化-脱溴方法合成溴化噻唑
标题:顺序溴化-脱溴方法合成溴化噻唑
摘要:溴噻唑全家族的合成已被重新研究,以更新和优化其生产.报告的物种包括2-溴噻唑,4-溴噻唑,5-溴噻唑,2,4-二溴噻唑,2,5-二溴噻唑,4,5-二溴噻唑和2,4,5-三溴噻唑,其中大多数是通过依次进行溴化和脱溴步骤.现在可以在不使用元素溴的情况下生产该完整家族,并且所提出的方法已允许首次报道该完整家族的物理和NMR光谱表征.
DOI:10.1021/acs.Joc.7B00495

专利信息

专利号:US-2025129021-A1
优先权日:2023-09-19
标题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-5986132-A
优先权日:1995-11-18
标题 :Synthesis of carboxylic acid derivatives
发明人：REEVE MAXWELL; BOWLES STEPHEN ARTHUR
权利人:BRITISH BIOTECH PHARM
摘要:Compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X are as defined in the specification and are prepared by elimination of one of the groups X 1 and X 2 from a compound of formula (II) wherein X 1 and X 2 each independently represent a carboxylic acid group or salt thereof, or a protected carboxylic acid group, the non-eliminated group X 1 or X 2 corresponding to the group X in the desired compound of formula (I). ##STR1##

专利号:WO-9719050-A1
优先权日:1995-11-18
标题:Synthesis of carboxylic acid derivatives

专利号:EP-0861226-A1
优先权日:1995-11-18
标题 :Synthesis of carboxylic acid derivatives

专利号:EP-0861226-B1
优先权日:1995-11-18
标题 :Synthesis of carboxylic acid derivatives